Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2

Conditions

Venous Thromboembolism 2Neoplasms 2Venous Thrombosis 1Thrombosis 1Pulmonary Embolism 1Multiple Myeloma 1Lymphoma 1Carcinoma, Ovarian Epithelial 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Tinzaparin × Clear all
NCT01817257 2018-10-29

ALICAT

Cardiff University

Phase 2 Terminated
2 enrolled
Classical hematology

Neoplasms, Pulmonary Embolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism

NCT00981903 2017-07-06

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

University of Southern California

Phase 2 Terminated
131 enrolled
Classical hematology

Neoplasms, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡